LLY

993.18

-1.57%↓

JNJ

202.82

+0.51%↑

ABBV

225.15

-0.48%↓

UNH

325.59

-1.49%↓

AZN

89.97

-0.23%↓

LLY

993.18

-1.57%↓

JNJ

202.82

+0.51%↑

ABBV

225.15

-0.48%↓

UNH

325.59

-1.49%↓

AZN

89.97

-0.23%↓

LLY

993.18

-1.57%↓

JNJ

202.82

+0.51%↑

ABBV

225.15

-0.48%↓

UNH

325.59

-1.49%↓

AZN

89.97

-0.23%↓

LLY

993.18

-1.57%↓

JNJ

202.82

+0.51%↑

ABBV

225.15

-0.48%↓

UNH

325.59

-1.49%↓

AZN

89.97

-0.23%↓

LLY

993.18

-1.57%↓

JNJ

202.82

+0.51%↑

ABBV

225.15

-0.48%↓

UNH

325.59

-1.49%↓

AZN

89.97

-0.23%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.03 -1.9

Buy Sell

Overview

Share price change

24h

Current

Min

1.03

Max

1.1

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+362.96% upside

Market Stats
By TradingEconomics
Market Cap	-6.9M 119M
Previous open	2.93
Previous close	1.03

News Sentiment

By Acuity

25%

75%

59 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 gru 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5 gru 2025, 21:08 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Buys AI-Device Maker Limitless

5 gru 2025, 19:39 UTC

Major Market Movers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 gru 2025, 19:17 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7 gru 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

7 gru 2025, 23:05 UTC

Market Talk

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7 gru 2025, 22:18 UTC

Market Talk

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6 gru 2025, 16:52 UTC

Acquisitions, Mergers, Takeovers

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 gru 2025, 10:30 UTC

Acquisitions, Mergers, Takeovers

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 gru 2025, 02:38 UTC

Acquisitions, Mergers, Takeovers

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 gru 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 gru 2025, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

5 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 gru 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 gru 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 gru 2025, 21:03 UTC

Market Talk

Earnings

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 gru 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 gru 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 gru 2025, 20:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 gru 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 gru 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 gru 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5 gru 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 gru 2025, 18:28 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:24 UTC

Acquisitions, Mergers, Takeovers

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

362.96% upside

12 Months Forecast

Average 5 USD 362.96%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

59 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.